The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/Objective-The lipid phosphate phosphatase 3 (LPP3) degrades bioactive lysophospholipids, including lysophosphatidic acid and sphingosine-1-phosphate, and thereby terminates their signaling effects. Although emerging evidence links lysophosphatidic acid to atherosclerosis and vascular injury responses, little is known about the role of vascular LPP3. The goal of this study was to determine the role of LPP3 in the development of vascular neointima formation and smooth muscle cells (SMC) responses. Methods and Results-We report that LPP3 is expressed in vascular SMC after experimental arterial injury. Using gain-and loss-of-function approaches, we establish that a major function of LPP3 in isolated SMC cells is to attenuate proliferation (extracellular signal-regulated kinases) activity, Rho activation, and migration in response to serum and lysophosphatidic acid. These effects are at least partially a consequence of LPP3-catalyzed lysophosphatidic acid hydrolysis. Mice with selective inactivation of LPP3 in SMC display an exaggerated neointimal response to injury. Conclusion-Our observations suggest that LPP3 serves as an intrinsic negative regulator of SMC phenotypic modulation and inflammation after vascular injury, in part, by regulating lysophospholipid signaling. These findings may provide a mechanistic link to explain the association between a PPAP2B polymorphism and coronary artery disease risk. (Arterioscler Thromb Vasc Biol. 2013;33:52-59.)
P henotypic modulation of smooth muscle cells (SMC)
occurs in response to vascular injury and is a critical component of the development of intimal hyperplasia, a defining feature of atherosclerotic and restenotic lesions. 1, 2 Lysophosphatidic acid (LPA) is a key component in serum 3 that promotes dedifferentiation, [3] [4] [5] proliferation, 6, 7 and migration [8] [9] [10] [11] of cultured SMC. On the basis of SMC responses to LPA and the related lysopholipid sphingosine-1-phoshate (S1P), these lipid mediators have been proposed to regulate SMC phenotypic modulation and the development of intimal hyperplasia in vivo. Both LPA and S1P elicit cellular effects through G-protein-coupled receptors. In the case of LPA, at least 6 and potentially 8 G-protein-coupled receptors exist that act through G i , G 12/13 , G q , and G s to stimulate intracellular signaling pathways to modulate cAMP production, 12, 13 the activity of phospholipase D activity, Rho GTPases 14 ; phospholipase C and protein kinase C 15 ; extracellular signal-regulated kinases (ERK) 16 ; and the initiation of Ca 2+ -transients. 17 Similar complex signaling systems exist for S1P. 18, 19 Evidence from studies using genetic and pharmacological approaches to target specific LPA and S1P receptors supports their role in regulating neointimal growth in response to vascular injury in mice. The development of intimal hyperplasia likely results from effects of LPA or S1P on multiple cell types, including recruitment of inflammatory and progenitor cells and stimulation of resident SMC. 4, [20] [21] [22] [23] [24] [25] Moreover, LPA heightens atherosclerotic plaque burden in apolipoprotein E-deficient (Apoe −/−) mice in an LPA 1 -and LPA 3 -dependent manner. 26 The signaling actions of LPA, and potentially S1P, can be terminated by enzymatic dephosphorylation catalyzed by lipid phosphate phosphatases (LPPs), which are cell surface integral membrane proteins. LPP3, encoded by the Ppap2b gene, is essential in mice for vascular development and gastrulation 27 and is expressed during development in heart cushions and valves. 28 Studies in cultured cells implicate LPP3 as both a regulator of vascular cell LPA responsiveness and a ligand for integrin αVβ3. 29, 30 However, because of the early embryonic lethality observed in mice lacking LPP3, a specific role for the enzyme in vascular cell function remains unknown. The identification of PPAP2B among 13 loci recently associated with coronary artery disease (CAD) in humans 31 suggests a causal relationship between LPP3 and vascular disease susceptibility.
In the present work, we identified SMC as a source of vascular LPP3 expression and sought to define a pathophysiologic role for SMC LPP3 in adult vascular tissue. We used genetic approaches to alter LPP3 expression and activity in SMC and investigate the consequences on vascular injury and isolated cellular responses. Using gain and loss-of-function approaches, we provide evidence that LPP3 regulates lysophospholipid signaling responses in SMC. Our findings implicate both LPP3 and lysophospholipids as pathophysiologically important regulators of SMC biology and may provide mechanistic insight into the association of an intronic single-nucleotide polymorphism in PPAP2B with CAD risk.
Methods
An expanded Materials and Methods section is available in the online-only Data Supplement data.
Mice
All procedures conformed to the recommendations of the Guide for the Care and Use of Laboratory Animals (Department of Health, Education, and Welfare publication number National Institutes of Health 78- 23, 1996) and were approved by the Institutional Animal Care and Use Committee. The production and initial characterization of mice in which the Ppap2b gene encoding LPP3 was flanked by lox-P sites (Ppap2b fl/fl ) has previously been described. 32, 33 Ppap2b fl/fl mice were backcrossed for >10 generations to the C57Bl/6 background and then crossed with C57Bl/6 mice expressing Cre recombinase under the control of the SM22 promoter 34 to obtain congenic SM-Ppap2b ∆ mice. The mice survived in the expected numbers. Mating of homogzygous Ppap2b fl/fl with SM-Ppap2b ∆ mice yielded 50% SM-Ppap2b ∆ offspring with <2% mortality. Mice were housed in cages with HEPA-filtered air in rooms on 12-hour light cycles and fed Purina 5058 rodent chow ad libitum. Systolic blood pressure and heart rate were measured for 5 consecutive days noninvasively in conscious mice using the CODA blood pressure analysis tail cuff system (Kent Scientific Corporation, Torrington, CT) daily after training for 1 week. Mean intra-arterial pressure was measured by placement of a 1.4 Fr Millar catheter in the carotid artery of isoflurane-anesthetized mice.
Vascular Injury
The left common carotid artery was dissected and ligated near the carotid bifurcation. All animals recovered and showed no symptoms of a stroke. At various intervals after carotid surgery, 35, 36 5 mm of carotid proximal to the suture were removed and processed for RNA analysis by qualitative polymerase chain reaction or analysis of protein markers by immunoblotting. Neointimal formation along the length of the vessel was assessed at 4 weeks after surgery using computer assisted morphometry as previously described. 36 Digital images were taken with a high-performance digital camera (resolution 3840 × 3072 pixels) attached to a Nikon 80i microscope with an X10 (NA=0.3) or X20 (NA=0.5) objective lens and analyzed with Metamorph software (Molecular Devices, Inc, Sunnyvale, CA).
Statistical Analysis
All results were expressed as mean±SD. In vitro studies were repeated a minimum of 3 times, and results were analyzed by Student t test or ANOVA. Statistical analysis was performed using Sigma-STAT software version 3.5 (Aspire Software, International, Ashburn, VA). A P<0.05 was considered significant.
Results

Upregulation of LPP3 in Neointimal Regions After Vascular Injury
As an initial approach to understanding the role of LPP3 in vascular disease, we profiled LPP3 expression in blood cells and in arterial vessels before and after vascular injury. Polymorphonuclear cells, but not other leukocytes or platelets, express detectable levels of LPP3 ( Figure I in the onlineonly Data Supplement). In carotid arteries, LPP3 expression was markedly upregulated in neointimal regions after ligation injury ( Figure 1 ). LPP3 protein ( Figure 1A ) and mRNA levels ( Figure 1B ) in carotid arteries were higher, most notable ≥14 days after injury. To localize LPP3 expression in injured vessels, immunostaining for LPP3 and the SMC α-actin marker was performed ( Figure 1C and 1D). The findings indicated that LPP3 expression co-localized in areas that contain SMCs after arterial injury ( Figure 1C , brown staining) and, in particular, in the neointimal region at 28 days after injury ( Figure  1D , yellow overlap). These results suggest that SMC are at least one source of neointimal LPP3. Indeed, isolated, cultured SMC from murine aorta expresses LPP3 ( Figure II in the online-only Data Supplement).
LPP3 Negatively Regulates LPA Signaling Responses in SMC
The LPP family of cell-surface-associated lipid phosphatases hydrolyzes and inactivates LPA and the related lysophospholipid S1P. Both bioactive lipids have been implicated as mediators of phenotypic modulation of vascular SMC responses in vivo and in vitro. The time course of upregulation of LPP3 expression in injured vessels is consistent with a role for the enzyme in downregulating lipid signaling, and thereby halting lysophospholipid-mediated inflammation, proliferation, and migration. We used isolated SMC to test the hypothesis that LPP3 alters SMC responses by attenuating LPA-mediated signaling. LPP3 was overexpressed in SMC using a recombinant lentiviral vector ( Figure IIA in the online-only Data Supplement). In comparison with control cells infected with green fluorescent protein-expressing virus, LPP3-overexpressing SMC cultured in serum (which contains μmol/L levels of LPA), displayed ≈2-fold less growth after 6 days (P<0.05; Figure IIB in the online-only Data Supplement). The effect of LPP3 was specific in that overexpression of LPP3 had no effect on growth in response to platelet-derived growth factor. In cells cultured in serum, LPP3 overexpression reduced ERK activity by ≈50% ( Figure IIC and IID in the online-only Data Supplement) and Rho activity by ≈75% ( Figure IIE The absence of LPP3 in SMC promoted LPA-mediated ERK activation by increasing and prolonging ERK phosphorylation ( Figure 2A ). In comparison with Ppap2b fl/fl cells, SM-Ppap2b ∆ cells demonstrated an ≈2-fold increase in LPA-induced ERK activation that persisted up to 60 minutes (P<0.001; Figure 2A left). Additionally, SM-Ppap2b ∆ cells responded to lower levels of LPA, with an ≈3-fold increase in ERK activation at 10 minutes in response to 0.25 μmol/L LPA (P<0.001; Figure 2A right). Expression of murine or human LPP3, but not a catalytically inactive LPP3 mutant, rescued the phenotype of SM-Ppap2b ∆ cells by reducing phosphorylation of ERK in response to LPA ( Figure 2B ). Consistent with these observations, LPP3 deficiency in SMC resulted in a 1.9-fold increase in LPA-mediated proliferation (P<0.001; Figure 2C ), which was not a result of a nonspecific enhancement of proliferation, because responses to platelet-derived growth factor were unaffected (not shown).
Rho activation in response to LPA was also enhanced in SM-Ppap2b ∆ cells (P<0.001) and was corrected by overexpression of either murine or human LPP3, but not a catalytically inactive mutant ( Figure 3A ). In keeping with heightened ERK and Rho activation, SMC-lacking LPP3 demonstrated a 2.3-fold increase in migration toward either LPA or fetal bovine serum (P<0.001; Figure 3B ). Migration of SM-Ppap2b ∆ cells was reduced to levels observed in Ppap2b fl/fl cells by reexpression of either murine or human LPP3 ( Figure 3C ) and abolished by Rho kinase and ERK inhibitors ( Figure 3D ).
To exclude the possibility that the results obtained in the SM-Ppap2b ∆ cells were a result of developmental abnormalities that altered SMC phenotype, engineered short hairpin RNAs were used to target Ppap2b expression and thereby reduce LPP3 expression in wild-type SMC ( Figure  IVA in the online-only Data Supplement). Decreased LPP3 expression with this approach significantly increased LPAstimulated ERK activity 1.7-fold (P<0.001; Figure IVB Direct measurements of intact cell LPA phosphatase activity demonstrated that exogenously applied LPA was degraded 3-fold more slowly by SM-Ppap2b∆ than control cells ( Figure 4A ). If the enhanced LPA-signaling of LPP3-deficient cells was a result of a reduction in LPA degradation, then the SM-Ppap2b∆ cells should respond normally to a poorly hydrolyzable receptor-active LPA mimetic, such as the ester-linked thiophosphate derivative (1-oleoyl-2-O-methyl-rac-glycerophosphothionate). In support of this idea, we found that 1-oleoyl-2-O-methyl-racglycerophosphothionate-stimulated ERK activation responses of Ppap2b fl/fl and SM-Ppap2b∆ cells were similar ( Figure 4B ). Having established that LPP3 downregulates SMC responses to LPA, we next investigated whether the enzyme regulates SMC responses to S1P. In a proliferation assay, expression of murine LPP3, but not a catalytically inactive LPP3 mutant, reduced SMC proliferation elicited by S1P ( Figure VA and VB in the online-only Data Supplement). In keeping with this observation, SM-Ppap2b ∆ cells displayed exaggerated responses to S1P (Supplemental Figure 5C ) but not platelet-derived growth factor ( Figure VD in the onlineonly Data Supplement). Together, these results indicate that LPP3 modulates SMC responses to the lysophospholipid mediators, LPA and S1P, likely by hydrolyzing and thereby inactivating their signaling capabilities.
Consequences of Genetic Deletion of SMC LPP3
Our in vitro analysis of LPP3 function in SMC is consistent with a model in which LPP3 attenuates lysophospholipidtriggered signaling responses. We and others have reported that LPA and S1P contribute to the development of intimal hyperplasia by stimulating SMC migration and vascular inflammation. 4, 5, 21 Therefore, upregulation of LPP3 expression after vascular injury could serve as an intrinsic mechanism to limit neointimal formation. To investigate this possibility, we examined injury responses in the Ppap2b fl/fl and SM-Ppap2b ∆ mice.
Consistent with SMC serving as a major source of vesselassociated LPP3, SM-Ppap2b∆ mice displayed attenuated upregulation of LPP3 after carotid ligation injury ( Figure 5A ). LPP3 expression in advential adipose cells was not affected by SM22-Cre expression ( Figure 5A arrowheads) . Dual staining for SMC α-actin and LPP3 indicated colocalization in Ppap2b fl/fl vessels after injury, and this colocalization was lacking in SM-Ppap2b∆ mice ( Figure 5B ). In the absence of SMC-LPP3, a more extensive neointimal layer formed along the length of the carotid arteries at 4 weeks after injury, as compared with control mice (Figure 5A and 5C ). Intima area ( Figure 5C ), intima/media ratio ( Figure 5E ), and lumen area ( Figure 5F ), but not medial area ( Figure 5D ), were all significantly greater in injured SM-Ppap2b∆ arteries. The findings probably do not reflect subtle differences in genetic background because no differences were observed in injury responses among Ppap2b fl/fl , SM22-Cre, and C57BL/6 mice ( Figure VI in the online-only Data Supplement).
To determine the molecular underpinnings of the enhanced injury response, we examined the consequences of LPP3 deficiency in more detail. After injury, ERK-activation in arterial tissue, as measured by the ratio of phospho-ERK to total ERK, increased and returned to baseline levels by 7 days in Ppap2b fl/fl mice. Vessels from the SM-Ppap2b∆ mice demonstrated a biphasic pattern of ERK activation with persistent elevation at day 14 ( Figure 6A and 6B and Figure VIIA in the online-only Data Supplement). Phosphohistone H3 staining was also enhanced in injured vessels from SM-Ppap2b∆ mice ( Figure VIIB in the online-only Data Supplement). The stereotypic injury response involves dedifferentiation and redifferentiation of SMC, which can be monitored by an initial decrease followed by a later increase in SMC differentiation markers in the vessel wall. In uninjured SM-Ppap2b∆ vessels, mRNA levels for the SMC differentiation markers, Acta2 (SM-actin), Tagln (SM22), Myh11 (SM-myosin heavy chain), and Cnn (calponin) were ≈1.8-, 2.3-, 3.9-, and 3.0-fold lower than levels observed in Ppap2b fl/fl arteries and, as expected, Ppap2b (LPP3) mRNA was dramatically reduced ( Figure 6C ). Dedifferentiation, as documented by a decline in Myh11 expression, occurred in both Ppap2b fl/fl and SM-Ppap2b∆ mice at 7 days after injury. However, the normal reexpression of Myh11 after 14 days was substantially blunted in SM-Ppap2b∆ mice ( Figure 6D ). Moreover, pronounced Il6 (interleukin-6) expression ( Figure  6E ) and vascular inflammation ( Figure 6F and Figure VIIC in the online-only Data Supplement) occurred in SM-Ppap2b∆ mice ≥14 days after vessel injury. No differences in LPA receptor mRNA levels were observed in aortas from SM-Ppap2b∆ and Ppap2b fl/fl mice (data not shown). Together, these observations demonstrate a role for SMC LPP3 in attenuating proliferative and inflammatory responses after vascular injury.
Blood pressure was similar in Ppap2b fl/fl and SM-Ppap2b ∆ mice, although heart rates were significantly higher in SM-Ppap2b ∆ mice (P<0.001; Table I in the online-only Data Supplement). The higher heart rates may reflect lower LPP3 expression in hearts ( Figure VIII in the online-only Data Supplement) resulting from SM22-mediated Cre recombination in cardiac tissue, which has been observed in other studies involving the SM22-Cre transgene. 37
Discussion
Our findings indicate that LPP3 is robustly expressed in SMC after arterial injury. After ligation injury, a substantial portion of LPP3 expression seems to occur in SMC with a time course consistent with a role in influencing vascular injury responses. Genetic evidence indicates that LPP3 negatively regulates SMC phenotypic modulation both in vitro and in vivo. Loss of LPP3 in SMC enhances intimal hyperplasia, prolongs SMC dedifferentiation, and promotes vascular inflammation after arterial injury. Studies in isolated cells support a model in which a function of LPP3 is to attenuate localized production or availability of bioactive lipid mediators. Specifically, overexpression of LPP3 reduces SMC migration and proliferation in response to LPA or S1P, whereas attenuation or elimination of LPP3 amplifies SMC responses to LPA. Taken together our observations suggest that LPP3 expression after vascular injury normally limits cellular responses to LPA and S1P and that reduced expression of LPP3 enhances SMC phenotypic modulation and vascular inflammation, likely in part by increasing their signaling. Although lack of LPP3 clearly impairs LPA degradation and inactivation, additional non-LPA-dependent mechanisms of LPP3 action could also affect SMC phenotypic modulation. For example, LPP3 may have nonenzymatic functions mediated by integrin binding or catenin signaling.. 27, 38, 39 A role for LPP3 in human vascular disease was suggested by the recent demonstration that an intronic, common singlenucleotide polymorphism variant in PPAP2B, rs17114036, strongly associates with atherosclerotic CAD, independent of traditional risk factors, such as total-high-density lipoprotein and low-density lipoprotein cholesterol, diabetes mellitus, body mass index, hypertension, or smoking. In this study, we offer support for a possible mechanistic link between this new CAD locus, LPP3 expression, and vascular disease. Our findings support a model in which genetic variants associated with lower LPP3 expression would be associated with exacerbated vascular injury responses.
Emerging evidence supports a role for lysophopsholipid mediators in regulation of vascular development and function. Our data add to the weight of the evidence that LPP3 regulates vascular cell function. Our findings provide functional evidence for a novel role for LPP3 and lipid signaling in adult vascular cells. If the enhanced inflammation and neointimal formation observed in mice lacking LPP3 in SMC reflects processes that occur in the development of atherosclerosis in humans, then our results may provide a mechanism by which alterations in LPP levels (or activity) could alter risk for CAD and MI in humans.
Heart, particularly atrial tissue, robustly expresses LPP3. SM22-Cre-mediated deletion of the floxed Ppap2b allele lowers LPP3 levels in heart, presumably because of recombination in cardiac tissue. This is associated with lower heart rates, which may indicate a role for LPP3 in regulating heart rate and function. Infusion of LPA in rabbits increases ventricular arrhythmia and the proportion of non-phosphorylated connexin 43, which may inhibit junction transmission. 40 Whether LPP3 regulates any of these responses is not known.
In summary, LPP3 expression in arterial tissue, and SMC in particular, increases after arterial injury. Enhanced LPP3 expression attenuates SMC proliferatory and migratory responses and may attenuate vascular inflammation. Mice lacking SMC-LPP display enhanced vascular inflammatory responses and development of intimal hyperplasia after injury. We propose that these observations reflect a role for LPP3 in attenuating local signaling by lysophospholipid mediators. Our observations may suggest novel strategies to attenuate vascular inflammation and suggest that a better understanding of genetic factors and environmental stimuli that alter LPP3 levels is warranted.
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